$4700-a-month treatment to slow Alzheimer’s disease gets TGA tick
Donanemab slows the rate of Alzheimer's disease progression by about a third, says Professor Ashley Bush.
The TGA has registered a $4700-a-month Alzheimer’s treatment to slow disease progression in patients with confirmed amyloid plaque in the brain and specific genetic profiles.
Eli Lily’s donanemab (Kisunla) is indicated for patients with mild cognitive impairment who do not carry apolipoprotein E ε4 (ApoE ε4), which is linked to a higher risk of brain swelling and bleeding.
Each infusion will cost around $4700 on a private script, but Eli Lilly has already applied for PBS funding, which the PBAC will assess in July.
The company said about 450,000 Australians could be eligible for initial assessment.
